Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Browse all Drug Analysis Profiles A–Z
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
Search EudraVigilance database
Browse substances A–Z in the European adverse reaction database
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
1 branded products available
Part of the Wasp-Eze brand family (generic: Benzocaine + Mepyramine)
MHRA licensed products
View all licensed products for Benzocaine + Mepyramine on the MHRA register
Therapeutically similar medicines
Similarity is based on WHO Anatomical Therapeutic Chemical (ATC) classification and on a factual NHS dm+d therapeutic-grouping code prefix. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
NHS prescribing volume and spending trends
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & safety information
Official UK regulator monitoring and safety alerts
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. BNF code shown is the factual mapping value distributed by NHS Business Services Authority (NHSBSA) in the dm+d supplementary file under OGL v3.0; it is not affiliated with, nor licensed from, the publishers of the British National Formulary.
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Academic studies and reviews for this medicine's active substance
Showing all 29 studies.
Reviews & meta-analyses: 1 · Randomised trials: 1 · 2017–2025
Showing all 29 studies, sorted by most relevant.
Manisha Nair, D. Gurunathan
Journal of Anaesthesiology, Clinical Pharmacology, 2019
BACKGROUND AND AIMS: Topical anesthetic agents are widely used in the field of pediatric dentistry to reduce pain and apprehension during administration of local anesthesia. Various topical anesthetic agents are available, among which the most commonly used ones are lignocaine and benzocaine. Hence we planned this study to compare and evaluate the effectiveness of topical anesthesia on needle insertion pain during administration of inferior alveolar nerve block. MATERIAL AND METHODS: This double blind clinical study included 30 children of 4-8 years of age who were divided equally into two groups: Group A-2% lignocaine hydrochloride gel (Lox 2%) and Group B-20% benzocaine gel (ProGel-B). The intervention involved assessment of pain perception by the child during administration of inferior alveolar nerve block. The child's pain assessment was done using modified Wong-Baker pain rating scale. The ratings were subjected to statistical analysis. RESULTS: value -0.000). CONCLUSION: This study demonstrates that there is a highly significant difference between the topical anesthetic effectiveness of 2% lignocaine and 20% benzocaine on needle insertion pain in inferior alveolar nerve block. Twenty percent benzocaine showed better results than 2% lignocaine in reducing the needle insertion pain.
Abstract licence: CC BY-NC-SA
S. Khair-ul-Bariyah, Muhammad Ali, M. I. Din, et al.
Mini reviews in medicinal chemistry, 2020
- Drug Development
- Anesthetics, Local
- Anti-Infective Agents
Shiman Lin, Bao-Zhu Jia, W. Luo, et al.
Food chemistry, 2023
- Carbon
- Quantum Dots
- Alkaline Phosphatase
Mona A. Mohamed, S. A. Atty, H. Merey, et al.
The Analyst, 2017
- Nanoparticles
- Antipyrine
- Benzocaine
-GO/CPE exhibits high sensitivity and good stability towards the sensing of BEN and ANT and has the potential to be utilised as a clinical assay and QA in pharmaceutical products.
Abstract licence: CC BY
N. Okur, E. Çağlar, Muhammet Davut Arpa, et al.
Pharmaceutical Development and Technology, 2017
- Skin Absorption
- Acrylic Resins
- Administration, Cutaneous
K. Munawar, Saqib Ali, Shabbir Muhammad, et al.
Arabian Journal for Science and Engineering, 2024
Stuart Barr, R. W. Elwood
Animals : an Open Access Journal from MDPI, 2024
Acceptance of the possibility of pain in animals usually requires that various criteria are fulfilled. One such criterion is that a noxious stimulus or wound would elicit directed rubbing or grooming at the site of the stimulus. There is also an expectation that local anaesthetics would reduce these responses to damage. These expectations have been fulfilled in decapod crustaceans but there has been criticism of a lack of replication. Here, we report an experiment on the effects of a noxious chemical, sodium hydroxide, applied to one eyestalk of the glass prawn. This caused an immediate escape tail-flick response. It then caused nipping and picking with the chelipeds at the treated eyestalk but much less so at the alternative eyestalk. Prior treatment with benzocaine also caused an immediate tail-flick and directed behaviour, suggesting that this agent is aversive. Subsequently, however, it reduced the directed behaviour caused by caustic soda. We thus demonstrated responses that are consistent with the idea of pain in decapod crustaceans.
Abstract licence: CC BY
M. Kurečič, Tina Maver, Natalija Virant, et al.
Cellulose, 2018
Sergio N. Bolasina, A. D. Azevedo, A. Petry
Aquaculture Reports, 2017
The aim of this study was to evaluate the anesthetic efficacy and determine the lowest effective concentration in the guppy, Poecilia vivipara. Fishes were exposed to benzocaine, tricaine methanesulfonate and eugenol at three different concentrations. After induction, they were transferred to an aquarium free of anesthetic for evaluating their recovery time. At the lowest concentration of the three anesthetics (50 mg L−1), fish did not reach complete induction. Time to accomplish a light sedation stage was significantly negative-related with concentration using tricaine (145 ± 13.4 s with 50 mg L−1 to 4.7 ± 0.7 s with 200 mg L−1) and benzocaine (152.8 ± 13 s with 50 mg L−1 to 4.0 ± 0.9 s with 200 mg L−1). For eugenol, significant differences were found between the lowest concentration, 50 mg L−1 (241 ± 57.6 s) with 100 mg L−1 (13.3 ± 3.9 s) and 200 mg L−1 (9.5 ± 2.6 s). Recovery times were significantly longer (P < 0.05) with the increase of eugenol concentration from 100 mg L−1 to 200 mg L−1, with no differences found between the different concentrations of benzocaine and tricaine. Complete induction times were significantly greater (P < 0.05) when using eugenol comparing with the other two anesthetic agents in fish exposed at the highest concentrations (200 mg L−1). This parameter showed a great dispersion when using eugenol at this concentration. Three fish exposed to 200 mg L−1 of eugenol did not recovered from the anesthetic after 180 s and presented ventilatory failure. Significantly shorter recovery times (P < 0.05) were found using tricaine comparing with eugenol (120 ± 24.8 s and 163.5 ± 57.1 s, respectively) at the higher concentration (200 mg L−1). The optimum dose rates of benzocaine and tricaine for induction within the efficacy criteria stated in this study was 200 mg L−1. It can be concluded these anesthetics are the more effective ones, being benzocaine more economically affordable for large-scale use on handling P. vivipara.
Abstract licence: CC BY-NC-ND
Beatriz Gneiding, Daniela Romani Bonotto, Fabiano Bendhack, et al.
Veterinary Research Communications, 2023
- Anesthetics
- Carps
- Fish Diseases
Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.
Scientific data (pharmacology, interactions, ADME) is not yet available for this medicine. Clinical sections are sourced from the NHS dm+d database.